Kronos Bio, Inc. - KRON STOCK NEWS

Kronos Bio, Inc. announced FDA clearance for its Investigational New Drug application for lanraplenib (LANRA) targeting acute myeloid leukemia (AML). The firm is set to launch a Phase 1/2 clinical trial in Q4 2021 and plans to initiate a Phase 3 trial for entospletinib (ENTO) in newly diagnosed NPM1-mutated AML patients. Financially, as of June 30, 2021, Kronos holds $419.3 million in cash, with a net loss of $29.1 million for Q2 2021. The company showcased its SYK inhibitor portfolio and plans to report key trial data in the coming months.

Kronos Bio has received FDA clearance for its IND application for lanraplenib (LANRA) to treat relapsed or refractory FLT3-mutated acute myeloid leukemia (AML). The first Phase 1/2 trial is set to begin in Q4 2021, with initial safety and efficacy data expected in late 2022. LANRA is positioned as a next-generation SYK inhibitor, with potential advantages in dosing compared to entospletinib (ENTO). The development strategy aims to leverage synergistic effects between LANRA and standard treatments to target genetic mutations in AML patients.

Kronos Bio, Inc. (Nasdaq: KRON) announced participation in two upcoming investor conferences. The management team will engage in fireside chats at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 10:30 a.m. ET, and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, 2021, at 11:20 a.m. ET. These discussions will be webcast live on the company's website, with replays available for one month after each event. Kronos Bio focuses on developing cancer therapies, including SYK inhibitors and CDK9 inhibitors, to target specific mutations in cancer.

Kronos Bio (KRON) has revealed its development strategy for the SYK inhibitor portfolio, particularly lanraplenib (LANRA) and entospletinib (ENTO), targeting acute myeloid leukemia (AML). The company plans to begin two Phase 1/2 trials for LANRA and a Phase 3 trial for ENTO aimed at patients with NPM1 mutations. Furthermore, initial data from KB-0742, a CDK9 inhibitor for MYC-dependent solid tumors, is expected by Q4 2021. These advancements aim to address the needs of AML patients with specific genetic mutations that account for over two-thirds of cases.

Kronos Bio, Inc. (Nasdaq: KRON) reported significant developments during its recent quarterly update. As of March 31, 2021, the company had $440.6 million in cash and equivalents. Highlights include preclinical data for KB-0742 presented at AACR, indicating sustained tumor growth inhibition in multiple cancers. The FDA approved a positive End-of-Phase 2 meeting for SYK inhibitor entospletinib, paving the way for a Phase 3 trial in AML. R&D expenses were $17.6 million, while the net loss stood at $26.1 million or $0.48 per share.

Kronos Bio, Inc. (Nasdaq: KRON) will participate in a fireside chat at the Bank of America Securities 2021 Health Care Conference on May 13, 2021, at 1:15 p.m. ET. The event will be available via live webcast on the company's website, with a replay archived for one month. Kronos Bio focuses on developing therapies for cancer, with lead investigational therapy entospletinib aimed at treating NPM1-mutated acute myeloid leukemia (AML) and another candidate, KB-0742, targeting MYC-amplified solid tumors.

Kronos Bio, Inc. (Nasdaq: KRON) presented preclinical data at the AACR Annual Meeting 2021 for KB-0742, an innovative CDK9 inhibitor targeting MYC-amplified tumors. The findings indicated sustained tumor growth inhibition via intermittent dosing, with MYC genomic amplification identified as a key sensitivity factor. Initial clinical trial data for KB-0742 is expected in Q4 2021, with hopes to confirm these promising preclinical results translating to effective treatments in patients.

Kronos Bio, Inc. (Nasdaq: KRON) mourns the loss of board member and early investor John C. Martin, Ph.D., who passed away recently. Martin was recognized for his significant contributions to the life sciences and was instrumental in the development of major HIV treatments during his tenure at Gilead Sciences. His legacy includes philanthropic efforts through The John C. Martin Foundation, focusing on healthcare access in underserved populations. Kronos Bio is committed to continuing Martin's vision of transforming cancer therapies through innovative research.

Kronos Bio (Nasdaq: KRON) announced the appointment of Taiyin Yang, Ph.D., to its board of directors. Dr. Yang brings over 40 years of experience in pharma development, including significant roles at Gilead Sciences, where she led the creation of innovative treatments. Her expertise is expected to aid Kronos in advancing its clinical pipeline. Additionally, Jakob Loven will not seek re-election at the 2021 Annual Meeting. This change comes during a critical growth phase for Kronos, focused on cancer therapies like entospletinib and KB-0742.